ALBUQUERQUE, N.M.--(BUSINESS WIRE)-- Cancer diagnostics company Biomoda, Inc. (OTCBB: BMOD) (www.biomoda.com) today announced that it has closed a private placement for gross proceeds of $560,000. Under the terms of the private placement, Biomoda has agreed to issue to investors (i) debentures convertible into shares of common stock and (ii) warrants to purchase 2,000,000 shares of common stock. The shares of common stock issuable upon conversion of the debentures and the exercise of warrants are restricted under Securities and Exchange Commission (SEC) Rule 144.
The convertible debentures will mature on August 31, 2011. The convertible debentures will bear interest at an annual rate of 10 percent of the principal amount of the debentures outstanding from time to time, payable in cash on the earlier of the conversion of the debenture or the maturity date.
“Continued support from the life-sciences investment community will help us bring our diagnostic for early-stage lung cancer to the marketplace,” said Biomoda President John Cousins. “Proceeds from this financing will be used to fund operations as we finalize the analysis of data from our pilot clinical study and prepare to launch the pivotal study, the final step before FDA approval.”
Biomoda’s CyPath® diagnostic assay binds to cancer cells and causes them to fluoresce under specific frequencies of light. Pending FDA approval as a Class III medical device, CyPath® is for investigational use only.
The securities described above were sold by Biomoda to non-affiliates in a private placement under Rule 144, a safe harbor that allows for the sale of restricted and affiliate securities in limited quantities without requiring the securities to be registered. This press release does not constitute an offer to sell any securities or a solicitation of an offer to purchase any securities.
Biomoda (www.biomoda.com) is a cancer diagnostics company focused on the development of accurate, inexpensive and noninvasive tests for the early detection of cancer. In addition to its first product for lung cancer, diagnostic assays for cervical, breast, colorectal, bladder, and oral cancers are targeted for development. Current research and development operations, laboratory functions and administrative offices are located in Albuquerque, N.M.
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are based on estimates, projections, beliefs and assumptions of Biomoda management at the time of such statements and are not guarantees of future performance. Forward-looking statements involve risks and uncertainties in predicting future results and conditions. Actual results could differ materially from those projected in these forward-looking statements due to a variety of factors, including, without limitation, the acceptance by customers of our products, our ability to develop new products cost-effectively, our ability to raise capital in the future, the development by competitors of products using improved or alternative technology, the retention of key employees and general economic conditions. The forward-looking statements contained herein are also subject generally to other risks and uncertainties that are described from time to time in the Company’s reports and registration statements filed with the Securities and Exchange Commission, including those under the heading "Risk Factors" in the Company's Annual Report on Form 10-K filed with the SEC on March 30, 2010. Forward-looking statements are made as of the date of this press release and are subject to change without notice.
Biomoda, Inc., Albuquerque
John Cousins, 505-821-0875
KEYWORDS: United States North America New Mexico
INDUSTRY KEYWORDS: Health Oncology FDA